Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hepatocellular Carcinoma
100%
Epigenetic Modification
100%
Precision Therapy
100%
Non-coding RNA (ncRNA)
50%
Genetic mutation
50%
Tumor Suppression
25%
Tumor Progression
25%
Therapeutic Strategies
25%
Recent Advances
25%
Cancer Causes
25%
Cancer Mortality
25%
Oncogenic Pathways
25%
Early Detection
25%
Histone Modification
25%
Complex Interactions
25%
Patient Selection
25%
Histone Deacetylase Inhibitor (HDACi)
25%
DNA Methyltransferase Inhibitor
25%
Clinical Translation
25%
Potential Biomarkers
25%
Tumor Therapy
25%
Hepatocarcinogenesis
25%
Aberrant DNA Methylation
25%
Dysregulated
25%
Therapeutic Targeting
25%
Immune Heterogeneity
25%
Tumor Treatment
25%
Epigenetic Landscape
25%
Tumor Immune Evasion
25%
JAK-STAT
25%
Diagnostic Strategy
25%
Epigenetic Therapy
25%
Therapy Resistance
25%
Sensitizing Effect
25%
Precise Therapeutics
25%
Early Phase Clinical Trials
25%
Treatment-related Adverse Events
25%
BET Inhibitor
25%
Early Prognosis
25%
Precise Diagnostics
25%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Biological Marker
100%
Neoplasm
50%
Untranslated RNA
50%
Tumor Growth
25%
Adverse Event
25%
Malignant Neoplasm
25%
Carcinogenesis
25%
Histone
25%
Liver Carcinogenesis
25%
Histone Deacetylase Inhibitor
25%
Bromodomain Inhibitor
25%
Therapy Resistance
25%
Biochemistry, Genetics and Molecular Biology
Non-Coding RNA
100%
Gene Mutation
100%
Tumor Progression
50%
DNA Methylation
50%
Carcinogenesis
50%
Histone Modification
50%
Epigenetic Therapy
50%
Tumor Escape
50%